Sanaria
Sanaria

WELCOME TO SANARIA

Sanaria is a biotechnology company dedicated to the production of a vaccine protective against malaria caused by the pathogen Plasmodium falciparum. Sanaria’s vaccine is based on an approach to immunization that has already proven highly protective in humans.
Learn more

Plasmodium falciparum malaria is responsible for more childhood mortality than any other single infectious agent. Sanaria’s vaccine development efforts are focused on African children, the population most urgently in need of protection.
Learn more

Sanaria

Sanaria's CEO, Stephen L. Hoffman, briefs Rep. Chris Van Hollen (MD-008), on Sanaria's Clinical Progress and Future Plans at the U.S. Capitol.

Learn more


Sanaria

Sanaria launches crowdfunding campaign for SporoBotTM, a mosquito dissecting robot.

Learn more
Press Release


Sanaria

Sanaria wins 2014 Best Prophylactic Vaccine at the 2014 World Vaccine Congress, Vaccine Industry Excellence Awards.

Learn more
Press Release

Sanaria

Sanaria wins the 2013 Verl Zanders Emerging Business of the Year Award from the Montgomery County Chamber of Commerce.

Sanaria Finalist Video
Learn more

SanariaSanaria's manufacturing facility

Science publishes Sanaria's Research Article, Protection Against Malaria by Intravenous Immunization with a Non-Replicating Sporozoite Vaccine

Sanaria Press Release
Summary
Podcast (starting at 11:52)
NIH Press Release
Navy Press Release
Nature
NPR
Washington Post
Sanaria

Sanaria Team Retreat
Sanaria's plans for development of its Sanaria® PfSPZ-based products


Learn more

What happens inside humans when a mosquito bites

Choumet, et al, PLOS 2012
National Geographic
Sanaria

Featured Employee
Eric R. James, PhD
Senior Director
Vaccine Stabilization and Logistics
Learn More


Sanaria

Sanaria hosted Maryland 6th District United States Congressman John Delaney. Representative Delaney toured Sanaria's facilities and received an overview of Sanaria's Clinical Development Program. (L to R) Rep. Delaney, Dr. B Kim Lee Sim and Dr. Stephen L Hoffman.


Sanaria

Sanaria participates in Rally for Medical Research to raise awareness of the critical need to make funding for the National Institutes of Health (NIH) a national priority, April, 2013.


Learn more

If you are interested in joining our team, please check our employment openings.

If you are interested in information about enrollment or participation in Sanaria's clinical trials, please contact us.

Follow us on Follow sanaria_inc on Twitter

 

Sanaria

August 2014
Sanaria recognized as a NIH SBIR/STTR Notable Succes Learn More

July 2014
First controlled human malaria infection in Africa shows that PfSPZ Challenge can be used for drug and vaccine development in the field American Society of Tropical Medicine and Hygiene's Press Release

July 2014
GSK submitted a regulatory application to the European Medicines Agency for its malaria vaccine candidate, RTS,S. Sanaria and GSK's different approaches explained in WSJ article.

March 2014
Sanaria wins Best Prophylactic Vaccine at the 2014 World Vaccine Congress, Vaccine Industry Excellence Awards, Press Release

March 2014
Dr. Peter Billingsley, Sanaria's Vice President International Projects and Strategy's article, Infection and treatment immunizations for successful parasite vaccines was selected as one of the top ten articles for 2013 by the Editorial Board of Trends in Parasitology

January 2014
Diosdado Vicente Nsue Milang, Equatorial Guinea's Minister of Health and Social Welfare Discusses Sanaria's Malaria Vaccine Clinical Trial

January 2014
Sanaria's Vice President International Projects and Strategy, Dr. Peter F. Billingsley, featured in Queen's University Alumni Review, Biology Grad Helping Develop Breakthrough Malaria Vaccine

October 2013
Sanaria's CEO, Dr. Stephen L. Hoffman, featured in Washingtonian Magazine, Dr. Hoffman vs. the Mosquito

October 2013
Sanaria is a proud sponsor of Frontiers in Science and Medicine Day 2013

October 2013
The Government of Equatorial Guinea announces a plan to work with Sanaria and its partners, Marathon and Medical Care Development International, to develop a program to use Sanaria's malaria vaccine to combat malaria on Bioko Island, Press Release

August 2013
Sanaria's future discussed in the Washington Business Journal

August 2013
Sanaria CEO, Dr. Stephen L. Hoffman answered questions about the SANARIA PfSPZ Vaccine on reddit's AMA

August 2013
Science publishes Sanaria's Research Article, Protection Against Malaria by Intravenous Immunization with a Non-Replicating Sporozoite Vaccine; Sanaria Press Release, Summary, Podcast, NIH Press Release, Navy Press Release, Nature, NPR, Washington Post

March 2013
Sanaria's CEO & CSO, Dr. Stephen L. Hoffman, ranked 21st out of the 50 most influential people in vaccines; 50 most influential

January 2013
In collaboration with the Radboud University Nijmegen Medical Center, a high level of controlled human malaria infection (CHMI) was achieved with Sanaria® PfSPZ Challenge paving the way towards the elimination of the need for live mosquito bites to test anti-malarial vaccines and drugs; AJTMH, Healio

January 2013
Sanaria Sr. Director, Dr. Eric James, publishes in Vaccine; Comparative cost models of a liquid nitrogen vapor phase (LNVP) cold chain-distributed cryopreserved malaria vaccine vs. a conventional vaccine

January 2013
Dr. Judith E. Epstein publishes in AJTMH; Taking a Bite out of Malaria: Controlled Human Malaria Infection by Needle and Syringe

January 2013
Sanaria featured in the BBC's news story, A Faster Path to a Possible Malaria Vaccine

October 2012
Sanaria is a proud sponsor of Frontiers in Science and Medicine Day 2012

June 2012
Sanaria and the Institute for Bioscience and Biotechnology Research of the University of Maryland College Park Awarded Collaborative, US $3M NIH Phase II Small Business Innovation Research Grant; Press Release

January 2012
The Sanaria®PfSPZ Vaccine is being assessed in a clinical trial at the Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health (Press Release). The VRC investigators are recruiting additional volunteers for the study (contact NIAID here and ask to participate in the Sanaria®PfSPZ Vaccine study)

Older News

 

disclaimer     site map

copyright(c) 2003-2014, Sanaria Inc., all rights reserved
website design by cymaxmedia.com